AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. AAPL
2. BRZE
3. TTAN
4. CHYM
5. USO
6. COO
7. IRT
8. QCOM
9. AEO
10. MSI

Go back to AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
AbbVie (NYSE: ABBV) Delayed: 250.91 +2.13 (0.86%)
Previous Close $248.78    52 Week High $68.12 
Open $247.73    52 Week Low $50.71 
Day High $251.18    P/E 54.43 
Day Low $246.77    EPS $4.61 
Volume 3,866,829